Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis

Infection and Immunity

Volumn 73, Issue 10, 2005, Pages 6372-6382

  Breton, Marie ^b   Tremblay, Michel J ^b   Ouellette, Marc ^b   Papadopoulou, Barbara ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; LIVE VACCINE; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION SENSITIVITY; INTERFERON PRODUCTION; LEISHMANIA DONOVANI; LEISHMANIA TARENTOLAE; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PARASITE VECTOR; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; T LYMPHOCYTE; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; DENDRITIC CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; TH1 CELLS;

EID: 25444511090     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.10.6372-6382.2005     Document Type: Article

References (78)

1. Abdelhak, S., H. Louzir, J. Timm, L. Blel, Z. Benlasfar, M. Lagranderie, M. Gheorghiu, K. Dellagi, and B. Gicquel. 1995. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141:1585-1592.
2. Ahmed, S., M. Colmenares, L. Soong, K. Goldsmith-Pestana, L. Munstermann, R. Molina, and D. McMahon-Pratt. 2003. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect. Immun. 71:401-410.
3. Alexander, J., G. H. Coombs, and J. C. Mottram. 1998. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161:6794-6801.
4. Ashford, R. W. 2001. Current usage of nomenclature for parasitic diseases, with special reference to those involving arthropods. Med. Vet. Entomol. 15:121-125.
5. Athman, R., and D. Philpott. 2004. Innate immunity via Toll-like receptors and Nod proteins. Curr. Opin. Microbiol. 7:25-32.
6. Badaro, R., T. C. Jones, E. M. Carvalho, D. Sampaio, S. G. Reed, A. Barral, R. Teixeira, and W. D. Johnson, Jr. 1986. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154:1003-1011.
7. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
8. Bennouna, S., S. K. Bliss, T. J. Curiel, and E. Y. Denkers. 2003. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J. Immunol. 171:6052-6058.
9. Boucher, N., F. McNicoll, C. Dumas, and B. Papadopoulou. 2002. RNA polymerase I-mediated transcription of a reporter gene integrated into different loci of Leishmania. Mol. Biochem. Parasitol. 119:153-158.
10. Brandonisio, O., R. Spinelli, and M. Pepe. 2004. Dendritic cells in Leishmania infection. Microbes Infect. 6:1402-1409.
11. Bretscher, P. A., J. N. Menon, and O. Ogunremi. 1996. Towards a strategy of universally efficacious vaccination against pathogens uniquely susceptible to cell-mediated attack. J. Biotechnol. 44:1-4.
12. Brun, R., and M. Schonenberger. 1979. Cultivation and in vitro cloning of procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Short communication. Acta Trop. 36:289-292.
13. Campos-Neto, A., J. R. Webb, K. Greeson, R. N. Coler, Y. A. Skeiky, and S. G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2828-2836.
14. Colmenares, M., A. L. Corbi, S. J. Turco, and L. Rivas. 2004. The dendritic cell receptor DC-SIGN discriminates among species and life cycle forms of Leishmania. J. Immunol. 172:1186-1190.
15. Colmenares, M., A. Puig-Kroger, O. Muniz Pello, A. L. Corbi, and L. Rivas. 2002. Dendritic-cell specific ICAM-3 grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human dendritic cells, is a receptor for Leishmania amastigotes. J. Biol. Chem. 16:16.
16. Daneshvar, H., G. H. Coombs, P. Hagan, and R. S. Phillips. 2003. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 187:1662-1668.
17. Davoudi, N., C. A. Tate, C. Warburton, A. Murray, F. Mahboudi, and W. R. McMaster. 2005. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine 23:1170-1177.
18. Desjeux, P., and J. Alvar. 2003. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol. 97(Suppl. 1):3-15.
19. Dole, V. S., V. S. Raj, A. Ghosh, R. Madhubala, P. J. Myler, and K. D. Stuart. 2000. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 19:423-430.
20. Dumas, C., A. Muyombwe, G. Roy, C. Matte, M. Ouellette, M. Olivier, and B. Papadopoulou. 2003. Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect. Immun. 71:6499-6509.
21. Edwards, J. C., A. D. Sedgwick, and D. A. Willoughby. 1981. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J. Pathol. 134:147-156.
22. Ghosh, R. 2001. Separation of proteins using hydrophobic interaction membrane chromatography. J. Chromatogr. A 923:59-64.
23. Giacomini, E., E. Iona, L. Ferroni, M. Miettinen, L. Fattorini, G. Orefici, I. Julkunen, and E. M. Coccia. 2001. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J. Immunol. 166:7033-7041.
24. Gonzalo, R. M., G. del Real, J. R. Rodriguez, D. Rodriguez, R. Heljasvaara, P. Lucas, V. Larraga, and M. Esteban. 2002. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20:1226-1231.
25. Greenblatt, C. L. 1980. The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47:259-285.
26. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
27. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:229-243.
28. Handman, E., F. M. Symons, T. M. Baldwin, J. M. Curtis, and J. P. Scheerlinck. 1995. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect. Immun. 63:4261-4267.
29. Henri, S., J. Curtis, H. Hochrein, D. Vremec, K. Shortman, and E. Handman. 2002. Hierarchy of susceptibility of dendritic cell subsets to infection by Leishmania major: inverse relationship to interleukin-12 production. Infect. Immun. 70:3874-3880.
30. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
31. Hoover, D. L., D. S. Finbloom, R. M. Crawford, C. A. Nacy, M. Gilbreath, and M. S. Meltzer. 1986. A lymphokine distinct from interferon-gamma that activates human monocytes to kill Leishmania donovani in vitro. J. Immunol. 136:1329-1333.
32. Kellina, O. I. 1981. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R. Bull. Soc. Pathol. Exot. Fil. 74:306-318.
33. Khalil, E. A., A. M. El Hassan, E. E. Zijlstra, M. M. Mukhtar, H. W. Ghalib, B. Musa, M. E. Ibrahim, A. A. Kamil, M. Elsheikh, A. Babiker, and F. Modabber. 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565-1569.
34. Kole, L., L. Das, and P. K. Das. 1999. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J. Infect. Dis. 180:811-820.
35. Matte, C., and M. Olivier. 2002. Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators. J. Infect. Dis. 185:673-681.
36. Mauel, J. 1990. Macrophage-parasite interactions in Leishmania infections. J. Leukoc. Biol. 47:187-193.
37. Melby, P. C., G. B. Ogden, H. A. Flores, W. Zhao, C. Geldmacher, N. M. Biediger, S. K. Ahuja, J. Uranga, and M. Melendez. 2000. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68:5595-5602.
38. Mendez, S., Y. Belkaid, R. A. Seder, and D. Sacks. 2002. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
39. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
40. Mendez, S., K. Tabbara, Y. Belkaid, S. Bertholet, D. Verthelyi, D. Klinman, R. A. Seder, and D. L. Sacks. 2003. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 71:5121-5129.
41. Mendonca, S. C., D. G. Russell, and S. G. Coutinho. 1991. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin. Exp. Immunol. 83:472-478.
42. Momeni, A. Z., T. Jalayer, M. Emamjomeh, A. Khamesipour, F. Zicker, R. L. Ghassemi, Y. Dowlati, I. Sharifi, M. Aminjavaheri, A. Shafiei, M. H. Alimohammadian, R. Hashemi-Fesharki, K. Nasseri, T. Godal, P. G. Smith, and F. Modabber. 1999. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17:466-472.
43. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppola, Z. E. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
44. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J. Infect. Dis. 157:973-978.
45. Murray, H. W., J. J. Stern, K. Welte, B. Y. Rubin, S. M. Carriero, and C. F. Nathan. 1987. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J. Immunol. 138:2290-2297.
46. Muyombwe, A., M. Olivier, P. Harvie, M. G. Bergeron, M. Ouellette, and B. Papadopoulou. 1998. Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene. J. Infect. Dis. 177:188-195.
47. Nadim, A., E. Javadian, G. Tahvildar-Bidruni, and M. Ghorbani. 1983. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Fil. 76:377-383.
48. Papadopoulou, B., G. Roy, M. Breton, C. Kundig, C. Dumas, I. Fillion, A. K. Singh, M. Olivier, and M. Ouellette. 2002. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70:62-68.
49. Papadopoulou, B., G. Roy, and M. Ouellette. 1992. A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J. 11:3601-3608.
50. Pearson, R. D., and A. Q. Sousa. 1996. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22:1-13.
51. Prina, E., S. Z. Abdi, M. Lebastard, E. Perret, N. Winter, and J. C. Antoine. 2004. Dendritic cells as host cells for the promastigote and amastigote stages of Leishmania amazonensis: the role of opsonins in parasite uptake and dendritic cell maturation. J. Cell Sci. 117:315-325.
52. Rafati, S., A. H. Salmanian, T. Taheri, M. Vafa, and N. Fasel. 2001. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19:3369-3375.
53. Reed, S. G., and A. Campos-Neto. 2003. Vaccines for parasitic and bacterial diseases. Curr. Opin. Immunol. 15:456-460.
54. Roy, G., C. Dumas, D. Sereno, Y. Wu, A. K. Singh, M. J. Tremblay, M. Ouellette, M. Olivier, and B. Papadopoulou. 2000. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol. Biochem. Parasitol. 110:195-206.
55. Saravia, N. G., M. H. Hazbon, Y. Osorio, L. Valderrama, J. Walker, C. Santrich, T. Cortazar, J. H. Lebowitz, and B. L. Travi. 2005. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. Vaccine 23:984-995.
56. Scott, P., and C. A. Hunter. 2002. Dendritic cells and immunity to leishmaniasis and toxoplasmosis. Curr. Opin. Immunol. 14:466-470.
57. Sereno, D., M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 42:3097-3102.
58. Sharifi, I., A. R. FeKri, M. R. Aflatonian, A. Khamesipour, A. Nadim, M. R. Mousavi, A. Z. Momeni, Y. Dowlati, T. Godal, F. Zicker, P. G. Smith, and F. Modabber. 1998. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351:1540-1543.
59. Skeiky, Y. A., R. N. Coler, M. Brannon, E. Stromberg, K. Greeson, R. T. Crane, J. R. Webb, A. Campos-Neto, and S. G. Reed. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20:3292-3303.
60. Soussi, N., G. Milon, J. H. Colle, E. Mougneau, N. Glaichenhaus, and P. L. Goossens. 2000. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect. Immun. 68:1498-1506.
61. Spath, G. F., L. Epstein, B. Leader, S. M. Singer, H. A. Avila, S. J. Turco, and S. M. Beverley. 2000. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. USA 97:9258-9263.
62. Squires, K. E., F. Rosenkaimer, J. A. Sherwood, A. L. Forni, J. B. Were, and H. W. Murray. 1993. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am. J. Trop. Med. Hyg. 48:666-669.
63. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J. Immunol. 143:4244-4249.
64. Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
65. Sukumaran, B., and R. Madhuhala. 2004. Leishmaniasis: current status of vaccine development. Curr. Mol. Med. 4:667-679.
66. Sukumaran, B., P. Tewary, S. Saxena, and R. Madhubala. 2003. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21:1292-1299.
67. Sundar, S., K. Pai, R. Kumar, K. Pathak-Tripathi, A. A. Gam, M. Ray, and R. T. Kenney. 2001. Resistance to treatment in Kala-azar: speciation of isolates from northeast India. Am. J. Trop. Med. Hyg. 65:193-196.
68. Sundar, S., S. G. Reed, S. Sharma, A. Mehrotra, and H. W. Murray. 1997. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56:522-525.
69. Taylor, A. P., and H. W. Murray. 1998. Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis. J. Infect. Dis. 178:908-911.
70. Titus, R. G., F. J. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92:10267-10271.
71. Uzonna, J. E., G. F. Spath, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172:3793-3797.
72. von Stebut, E., and M. C. Udey. 2004. Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect. 6:1102-1109.
73. von Stebut, E., Y. Belkaid, T. Jakob, D. L. Sacks, and M. C. Udey. 1998. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188:1547-1552.
74. Webb, J. R., A. Campos-Neto, P. J. Ovendale, T. I. Martin, E. J. Stromberg, R. Badaro, and S. G. Reed. 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:3279-3289.
75. -). Immunology 85:1-7.
76. Zaph, C., J. Uzonna, S. M. Beverley, and P. Scott. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10:1104-1110.
77. Zhao, C., R. Cantin, M. Breton, B. Papadopoulou, and M. J. Tremblay. 2005. DC-SIGN-mediated transmission of HIV-1 is compromised by the ability of Leishmania infantum to exploit also DC-SIGN as a ligand. J. Infect. Dis. 191:1665-1669.
78. Zinkernagel, R. M., M. F. Bachmann, T. M. Kundig, S. Oehen, H. Pirchet, and H. Hengartner. 1996. On immunological memory. Annu. Rev. Immunol. 14:333-367.